Intuitive Surgical Inc. (ISRG) is still expanding the reach of its da Vinci surgical system. This Zacks Rank #1 (Strong Buy) stock is expected to grow earnings in the double-digits in 2026 and 2027, highlights Tracey Ryniec, senior stock strategist at Zacks Investment Research.
Intuitive is a leader in minimally invasive care and the pioneer of robotic-assisted surgery. Its technologies include the da Vinci surgical system and the Ion endoluminal system. As of Dec. 31, more than 20 million patients worldwide had been operated on using da Vinci surgical systems.
On March 2, Intuitive announced that it had completed the acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates. This business is in Italy, Spain, Portugal, Malta, San Marino, and associated territories. The acquisition will provide more agile customer service and can bring the systems to more patients across Southern Europe.
Source: Zacks Investment Research
On Jan. 22, Intuitive Surgical reported its fourth quarter 2025 earnings – and it beat on the Zacks Consensus for the twelfth quarter in a row. Earnings were $2.53, compared to the Zacks Consensus of $2.25, good for a beat of $0.28.
Its last miss was all the way back in 2023. Intuitive has only missed twice in the last five years. Ten estimates were revised higher for 2026 since the earnings in January, but one has also been revised higher in the last month. That has pushed the 2026 Zacks Consensus up to $10.06 from $9.61 just two months ago.
Intuitive is not a cheap stock, but it hasn’t been for years. It trades with a forward price-to-earnings (P/E) ratio of 48. Investors are buying the growth.
Recommended Action: Buy ISRG.
